ketoconazole has been researched along with Nail Fungus in 91 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In order to assess the safety and efficacy of once-weekly fluconazole orally (100, 150, or 300 mg) with once-a-day topical application of 1% ketoconazole cream in the treatment of onychomycosis in Japan, 121 patients were assigned to one of three fluconazole dosages (100, 150, or 300 mg) and took fluconazole orally, once weekly, for 12 months or until a complete cure was achieved." | 9.11 | Combination therapy of once-weekly fluconazole (100, 150, or 300 mg) with topical application of ketoconazole cream in the treatment of onychomycosis. ( Chen, X; Hiruma, M; Ogawa, H; Shiraki, Y, 2004) |
| "To evaluate the incidence, severity, and course of ketoconazole-associated hepatic injury, 211 patients with onychomycosis were randomized by a ratio of 2:1 to receive either ketoconazole (137 patients) or griseofulvin (74 patients)." | 9.08 | Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study. ( Chien, RN; Liaw, YF; Lin, PY; Yang, LJ, 1997) |
| "An open, comparative, randomized study was conducted using griseofulvin or itraconazole for the treatment of onychomycosis of the foot." | 9.07 | Onychomycosis treated with itraconazole or griseofulvin alone with and without a topical antimycotic or keratolytic agent. ( Arenas, R; Domínguez, L; Fernández, G, 1991) |
| "Sixty-one patients with a clinical diagnosis of onychomycosis in finger or toe nails were treated with itraconazole 100 mg/day or griseofulvin 500 mg/day for six to nine months." | 9.07 | Efficacy and safety of itraconazole in the long-term treatment of onychomycosis. ( Blomqvist, K; Brandt, H; Havu, V; Hollmen, A; Kohtamäki, K; Lehtonen, L; Piepponen, T; Turjanmaa, K, 1992) |
| "In an open study 58 patients with chronic dermatophytosis mainly caused by Trichophyton rubrum and five patients with Tinea capitis were treated with ketoconazole." | 9.05 | Oral ketoconazole as an alternative to griseofulvin in recalcitrant dermatophyte infections and onychomycosis. ( Svejgaard, E, 1985) |
| "Determination of the most cost-effective oral drug treatment of onychomycosis of the toenails in the Dutch situation, by comparing griseofulvin, itraconazole, ketoconazole and terbinafine." | 7.69 | [Oral treatment of onychomycosis of the toe nails; comparison of cost-effectiveness of griseofulvin, itraconazole, ketoconazole and terbinafine]. ( Bergman, W; Rutten, FF, 1994) |
| "Nail-matrix kinetics were studied in 21 patients (19 with onychomycosis, two with tinea corporis) as soon as taking itraconazole (Sporanox) 100 mg daily for up to 7 months." | 7.68 | Itraconazole penetrates the nail via the nail matrix and the nail bed--an investigation in onychomycosis. ( Cauwenbergh, G; De Doncker, P; Dockx, P; Janssen, PA; Matthieu, L; van de Velde, V; Woestenborghs, R, 1991) |
| "This study was designed to investigate itraconazole nail kinetics in 39 patients with onychomycosis in relation to their therapeutic outcome." | 7.68 | Posttreatment itraconazole levels in the nail. New implications for treatment in onychomycosis. ( Cauwenbergh, G; De Doncker, P; Heykants, J; Roseeuw, D; Van Cutsem, J; Van de Velde, V; Willems, J; Willemsen, M; Woestenborghs, R, 1992) |
| "We have treated 48 cases of onychomycosis (of which 37 were caused by dermatophytes, 10 by yeasts and one by Scopulariopsis brevicaulis) with 200 mg ketoconazole daily." | 7.67 | [Ketoconazole and onychomycosis]. ( Achten, G; André, J; Parent, D; Wiame, L, 1984) |
| "Thirteen of sixteen patients with onychomycosis who were treated with a 40 percent urea cream in order to remove the diseased nail and then treated with ketoconazole, 200 mg a day orally, for three months, were cured of the disease." | 7.66 | Treatment of onychomycosis with ketoconazole and nonsurgical avulsion of the affected nail. ( Isordia, E; Loredo, CE; Moncada, B, 1983) |
| "17 patients with proven onychomycosis were treated with Ketoconazole (200 mg daily) over 6 months." | 7.66 | [Preliminary experiences in the treatment of onychomycosis with ketoconazole]. ( Trost, T, 1983) |
| "In order to assess the safety and efficacy of once-weekly fluconazole orally (100, 150, or 300 mg) with once-a-day topical application of 1% ketoconazole cream in the treatment of onychomycosis in Japan, 121 patients were assigned to one of three fluconazole dosages (100, 150, or 300 mg) and took fluconazole orally, once weekly, for 12 months or until a complete cure was achieved." | 5.11 | Combination therapy of once-weekly fluconazole (100, 150, or 300 mg) with topical application of ketoconazole cream in the treatment of onychomycosis. ( Chen, X; Hiruma, M; Ogawa, H; Shiraki, Y, 2004) |
| "To evaluate the incidence, severity, and course of ketoconazole-associated hepatic injury, 211 patients with onychomycosis were randomized by a ratio of 2:1 to receive either ketoconazole (137 patients) or griseofulvin (74 patients)." | 5.08 | Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study. ( Chien, RN; Liaw, YF; Lin, PY; Yang, LJ, 1997) |
| "An open, comparative, randomized study was conducted using griseofulvin or itraconazole for the treatment of onychomycosis of the foot." | 5.07 | Onychomycosis treated with itraconazole or griseofulvin alone with and without a topical antimycotic or keratolytic agent. ( Arenas, R; Domínguez, L; Fernández, G, 1991) |
| "Sixty-one patients with a clinical diagnosis of onychomycosis in finger or toe nails were treated with itraconazole 100 mg/day or griseofulvin 500 mg/day for six to nine months." | 5.07 | Efficacy and safety of itraconazole in the long-term treatment of onychomycosis. ( Blomqvist, K; Brandt, H; Havu, V; Hollmen, A; Kohtamäki, K; Lehtonen, L; Piepponen, T; Turjanmaa, K, 1992) |
| "In an open study 58 patients with chronic dermatophytosis mainly caused by Trichophyton rubrum and five patients with Tinea capitis were treated with ketoconazole." | 5.05 | Oral ketoconazole as an alternative to griseofulvin in recalcitrant dermatophyte infections and onychomycosis. ( Svejgaard, E, 1985) |
| " Though griseofulvin was introduced in the late 1950s and was at the time the only Food and Drug Administration (FDA)-approved drug in the United States for the systemic treatment of onychomycosis, its cure rate seldom exceeds 40%." | 4.82 | The systemic treatment of onychomycosis. ( Wenig, JA, 2004) |
| "Problems with the use of griseofulvin and ketoconazole in the treatment of onychomycosis have led to studies of three new oral antifungal drugs to treat this disease: fluconazole, itraconazole, and terbinafine." | 4.79 | Current trends in onychomycosis therapy: a literature review. ( Hecker, D, 1997) |
| " Griseofulvin, the only drug approved by the Food and Drug Administration for the systemic treatment of onychomycosis, has a cure rate that seldom exceeds 40%." | 4.79 | The systemic treatment of onychomycosis. ( Wenig, JA, 1995) |
| "Oral griseofulvin has been the first-line drug in the therapy of dermatophyte onychomycosis for many years." | 4.79 | Oral therapeutic agents in fungal nail disease. ( Roberts, DT, 1994) |
| "An economic analysis of the oral antifungal drugs griseofulvin (GRI), ketoconazole (KET), and terbinafine (TER), currently registered and used in treating onychomycosis of fingernails and toenails, was performed using a model that incorporates elements of both meta-analysis and pharmacoeconomics." | 4.79 | Cost-effectiveness analysis for onychomycosis therapy in Canada from a government perspective. ( Arikian, SR; Einarson, TR; Shear, NH, 1994) |
| " We conducted a multinational cost-effectiveness analysis, from a government payer perspective, comparing four primary oral treatment regimens for onychomycosis of the fingernails and toenails: griseofulvin, itraconazole, ketoconazole and terbinafine." | 4.79 | A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. The Onychomycosis Study Group. ( Arikian, SR; Einarson, TR; Kobelt-Nguyen, G; Schubert, F, 1994) |
| "The purpose of this article is to review the pharmacologic properties of two newer agents, itraconazole and terbinafine, and to assess their clinical efficacy in onychomycosis." | 4.78 | New approaches to the treatment of onychomycosis. ( De Doncker, P; Roseeuw, D, 1993) |
| "The aim of the present research work was to develop ketoconazole microemulsion-loaded hydrogel formulation containing nigella oil as permeation enhancer for the treatment of onychomycosis." | 3.91 | Formulation evaluation of ketoconazole microemulsion-loaded hydrogel with nigella oil as a penetration enhancer. ( Amra, K; Momin, M, 2019) |
| "The purpose of this investigation was to study the physico-chemical properties of hot-melt extruded films containing ketoconazole and to determine the influence of 'nail etching' on film bioadhesion and drug permeability for the assessment of topical onychomycosis therapies." | 3.72 | Influence of human nail etching for the assessment of topical onychomycosis therapies. ( Mididoddi, PK; Repka, MA; Stodghill, SP, 2004) |
| "Onychomycosis of the toenails is a condition that responds poorly to griseofulvin." | 3.70 | A questionnaire study on the management of onychomycosis: a Canadian perspective. ( Gupta, AK; Shear, NH, 1998) |
| "Determination of the most cost-effective oral drug treatment of onychomycosis of the toenails in the Dutch situation, by comparing griseofulvin, itraconazole, ketoconazole and terbinafine." | 3.69 | [Oral treatment of onychomycosis of the toe nails; comparison of cost-effectiveness of griseofulvin, itraconazole, ketoconazole and terbinafine]. ( Bergman, W; Rutten, FF, 1994) |
| "This study was designed to investigate itraconazole nail kinetics in 39 patients with onychomycosis in relation to their therapeutic outcome." | 3.68 | Posttreatment itraconazole levels in the nail. New implications for treatment in onychomycosis. ( Cauwenbergh, G; De Doncker, P; Heykants, J; Roseeuw, D; Van Cutsem, J; Van de Velde, V; Willems, J; Willemsen, M; Woestenborghs, R, 1992) |
| "Nail-matrix kinetics were studied in 21 patients (19 with onychomycosis, two with tinea corporis) as soon as taking itraconazole (Sporanox) 100 mg daily for up to 7 months." | 3.68 | Itraconazole penetrates the nail via the nail matrix and the nail bed--an investigation in onychomycosis. ( Cauwenbergh, G; De Doncker, P; Dockx, P; Janssen, PA; Matthieu, L; van de Velde, V; Woestenborghs, R, 1991) |
| "We have treated 48 cases of onychomycosis (of which 37 were caused by dermatophytes, 10 by yeasts and one by Scopulariopsis brevicaulis) with 200 mg ketoconazole daily." | 3.67 | [Ketoconazole and onychomycosis]. ( Achten, G; André, J; Parent, D; Wiame, L, 1984) |
| "17 patients with proven onychomycosis were treated with Ketoconazole (200 mg daily) over 6 months." | 3.66 | [Preliminary experiences in the treatment of onychomycosis with ketoconazole]. ( Trost, T, 1983) |
| "Thirteen of sixteen patients with onychomycosis who were treated with a 40 percent urea cream in order to remove the diseased nail and then treated with ketoconazole, 200 mg a day orally, for three months, were cured of the disease." | 3.66 | Treatment of onychomycosis with ketoconazole and nonsurgical avulsion of the affected nail. ( Isordia, E; Loredo, CE; Moncada, B, 1983) |
| "Ketoconazole is an effective treatment for chronic superficial candidiasis as well as chronic dermatophytosis." | 3.66 | Ketoconazole in the treatment of fungal infection. Clinical and laboratory studies. ( Hay, RJ, 1983) |
| "On further follow up, recurrence of onychomycosis was recorded in two patients in group I." | 2.73 | Combination of surgical avulsion and topical therapy for single nail onychomycosis: a randomized controlled trial. ( Bansal, S; Grover, C; Kumar, V; Nanda, S; Reddy, BS, 2007) |
| "Onychomycosis has been treated for years with oral antifungal agents, and more recently in the United States with a topical nail lacquer." | 2.42 | The use of oral antifungal agents to treat onychomycosis. ( Gupta, AK; Ryder, JE, 2003) |
| "rubrum." | 2.40 | Childhood white superficial onychomycosis caused by Trichophyton rubrum: report of seven cases and review of the literature. ( Lucky, AW; Ploysangam, T, 1997) |
| " In addition, the short treatment times (< 3 months) and intermittent dosing schedules are likely to enhance compliance and reduce the costs of therapy." | 2.40 | Onychomycosis: pathogenesis, diagnosis, and management. ( Elewski, BE, 1998) |
| "The management of onychomycosis has changed considerably in the past few years." | 2.38 | Onychomycosis. Agents of choice. ( Hay, RJ, 1993) |
| "Clinical onychomycosis was found in 77 of the 152 diabetics tested giving a prevalence of 50." | 1.43 | Onychomycosis in diabetic patients in Fako Division of Cameroon: prevalence, causative agents, associated factors and antifungal sensitivity patterns. ( Atashili, J; Eba, M; Fuh, AN; Kwenti, ET; Mouliom, RN; Nchanji, GT; Njunda, AL, 2016) |
| "Ketoconazole was found to be relatively stable during the extrusion process." | 1.34 | Characterization of hot-melt extruded drug delivery systems for onychomycosis. ( Mididoddi, PK; Repka, MA, 2007) |
| "Ketoconazole is a useful alternative to griseofulvin when oral therapy is required and the causative organism is insensitive to griseofulvin, or infection fails to respond to griseofulvin, or griseofulvin is contraindicated due to allergy, photosensitivity, porphyrinuria, intolerance, etc." | 1.27 | Consensus of the role and positioning of the imidazoles in the treatment of dermatophytosis. ( Jones, HE, 1986) |
| "Ketoconazole is an alternative when a replacement for griseofulvin is required, provided the degree of disability justifies the risk of drug toxicity." | 1.27 | Long-term ketoconazole treatment of chronic acral dermatophyte infections. ( Hersle, K; Mobacken, H; Moberg, S, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 36 (39.56) | 18.7374 |
| 1990's | 31 (34.07) | 18.2507 |
| 2000's | 15 (16.48) | 29.6817 |
| 2010's | 8 (8.79) | 24.3611 |
| 2020's | 1 (1.10) | 2.80 |
| Authors | Studies |
|---|---|
| Gnat, S | 1 |
| Łagowski, D | 1 |
| Nowakiewicz, A | 1 |
| Dyląg, M | 1 |
| Wang, F | 1 |
| Yang, P | 1 |
| Choi, JS | 1 |
| Antovski, P | 1 |
| Zhu, Y | 1 |
| Xu, X | 1 |
| Kuo, TH | 1 |
| Lin, LE | 1 |
| Kim, DNH | 1 |
| Huang, PC | 1 |
| Xu, H | 1 |
| Lee, CF | 1 |
| Wang, C | 1 |
| Hsu, CC | 1 |
| Chen, K | 1 |
| Weiss, PS | 1 |
| Tseng, HR | 1 |
| Amra, K | 1 |
| Momin, M | 1 |
| Hafeez, F | 1 |
| Hui, X | 1 |
| Chiang, A | 1 |
| Hornby, S | 1 |
| Maibach, H | 1 |
| Eba, M | 1 |
| Njunda, AL | 1 |
| Mouliom, RN | 1 |
| Kwenti, ET | 1 |
| Fuh, AN | 1 |
| Nchanji, GT | 1 |
| Atashili, J | 1 |
| Eichenfield, LF | 1 |
| Friedlander, SF | 1 |
| Zhao, Y | 1 |
| Li, L | 1 |
| Wang, JJ | 1 |
| Kang, KF | 1 |
| Zhang, QQ | 1 |
| Menéndez, S | 1 |
| Falcón, L | 1 |
| Maqueira, Y | 1 |
| Pin, D | 1 |
| Vidémont, E | 1 |
| Derian-Autier, D | 1 |
| Guillot, J | 1 |
| Plouzeau, E | 1 |
| Gupta, AK | 3 |
| Ryder, JE | 1 |
| Seebacher, C | 2 |
| Repka, MA | 2 |
| Mididoddi, PK | 2 |
| Stodghill, SP | 1 |
| Wenig, JA | 2 |
| Chen, X | 1 |
| Hiruma, M | 1 |
| Shiraki, Y | 1 |
| Ogawa, H | 1 |
| Crawford, F | 3 |
| Ferrari, J | 2 |
| Figueiredo, VT | 1 |
| de Assis Santos, D | 1 |
| Resende, MA | 1 |
| Hamdan, JS | 1 |
| Grover, C | 1 |
| Bansal, S | 1 |
| Nanda, S | 1 |
| Reddy, BS | 2 |
| Kumar, V | 1 |
| Méndez-Tovar, LJ | 1 |
| Manzano-Gayosso, P | 1 |
| Velásquez-Hernández, V | 1 |
| Millan-Chiu, B | 1 |
| Hernández-Hernández, F | 1 |
| Mondragón-González, R | 1 |
| López-Martínez, R | 1 |
| Parent, D | 1 |
| Achten, G | 2 |
| André, J | 2 |
| Wiame, L | 1 |
| Henning, H | 1 |
| Kasper, B | 1 |
| Lüders, CJ | 1 |
| Brugmans, J | 1 |
| Scheijgrond, H | 1 |
| Van Cutsem, J | 2 |
| Van den Bossche, H | 1 |
| Baisier, A | 1 |
| Hörig, C | 1 |
| Botter, AA | 2 |
| Nuijten, ST | 1 |
| Pfaff, G | 1 |
| Hay, RJ | 4 |
| van Dijke, CP | 1 |
| Boëtius, G | 1 |
| Peeters, JP | 1 |
| Peters, JH | 1 |
| Lozano, OW | 1 |
| Moncada, B | 1 |
| Loredo, CE | 1 |
| Isordia, E | 1 |
| Ramesh, V | 1 |
| Singh, R | 1 |
| Meinhof, W | 1 |
| Trost, T | 1 |
| Zaias, N | 2 |
| Drachman, D | 1 |
| Duarte, PA | 1 |
| Chow, CC | 1 |
| Simmons, F | 1 |
| Ruskin, J | 1 |
| Deutsch, PH | 1 |
| Quintiliani, R | 1 |
| Pérusse, R | 1 |
| Bergman, W | 1 |
| Rutten, FF | 1 |
| Roberts, DT | 1 |
| Crozier, WJ | 1 |
| Wise, KA | 1 |
| Einarson, TR | 2 |
| Arikian, SR | 2 |
| Shear, NH | 2 |
| Kobelt-Nguyen, G | 1 |
| Schubert, F | 1 |
| Lavrijsen, AP | 1 |
| Balmus, KJ | 1 |
| Nugteren-Huying, WM | 1 |
| Roldaan, AC | 1 |
| van 't Wout, JW | 1 |
| Stricker, BH | 2 |
| Roseeuw, D | 2 |
| De Doncker, P | 3 |
| Ruutu, P | 1 |
| Karvonen, J | 1 |
| Desgarennes, MD | 1 |
| Godoy, MR | 1 |
| Palencia, AB | 1 |
| Chien, RN | 1 |
| Yang, LJ | 1 |
| Lin, PY | 1 |
| Liaw, YF | 1 |
| Ploysangam, T | 1 |
| Lucky, AW | 1 |
| Bernuau, J | 1 |
| Durand, F | 1 |
| Pessayre, D | 1 |
| Hecker, D | 1 |
| Markinson, BC | 1 |
| Monter, SI | 1 |
| Cabrera, G | 1 |
| Hernanz Hermosa, JM | 1 |
| Lázaro Ochaita, P | 1 |
| Elewski, BE | 1 |
| Torres-Rodríguez, JM | 1 |
| Madrenys-Brunet, N | 1 |
| Siddat, M | 1 |
| López-Jodra, O | 1 |
| Jimenez, T | 1 |
| Van Puijenbroek, EP | 1 |
| Metselaar, HJ | 1 |
| Berghuis, PH | 1 |
| Zondervan, PE | 1 |
| Niewerth, M | 1 |
| Korting, HC | 1 |
| Del Rosso, JQ | 1 |
| Arrese, JE | 1 |
| Piérard-Franchimont, C | 1 |
| Piérard, GE | 1 |
| Young, P | 1 |
| Godfrey, C | 1 |
| Bell-Syer, SE | 1 |
| Hart, R | 1 |
| Brunt, E | 1 |
| Russell, I | 1 |
| Dethier, F | 1 |
| Mertens, RL | 1 |
| Morias, J | 1 |
| Peremans, W | 1 |
| Willemsen, M | 1 |
| Willems, J | 1 |
| Woestenborghs, R | 2 |
| Van de Velde, V | 2 |
| Heykants, J | 1 |
| Cauwenbergh, G | 2 |
| Baran, R | 1 |
| Piepponen, T | 1 |
| Blomqvist, K | 1 |
| Brandt, H | 1 |
| Havu, V | 1 |
| Hollmen, A | 1 |
| Kohtamäki, K | 1 |
| Lehtonen, L | 1 |
| Turjanmaa, K | 1 |
| Klausner, MA | 1 |
| Arenas, R | 1 |
| Fernández, G | 1 |
| Domínguez, L | 1 |
| Matthieu, L | 1 |
| Janssen, PA | 1 |
| Dockx, P | 1 |
| Hettinger, DF | 1 |
| Valinsky, MS | 1 |
| Knight, TE | 1 |
| Shikuma, CY | 1 |
| Knight, J | 1 |
| Walsøe, I | 1 |
| Stangerup, M | 1 |
| Svejgaard, E | 2 |
| Meyer, JC | 1 |
| Burri, C | 1 |
| Ruf, P | 1 |
| Schnyder, UW | 1 |
| Belukha, UK | 1 |
| Bidrat, MS | 1 |
| Luk'ianova, AS | 1 |
| Leshchenko, VM | 1 |
| Kukoleva, LI | 1 |
| Shirshikova, IuI | 1 |
| Rukavishnikova, VM | 1 |
| Dadiomova, VG | 1 |
| Clayton, YM | 1 |
| Moore, MK | 1 |
| Midgely, G | 1 |
| Rollman, O | 1 |
| Jameson, S | 1 |
| Lithell, H | 1 |
| Jones, HE | 1 |
| Markitziu, A | 1 |
| Katz, J | 1 |
| Pisanty, S | 1 |
| Török, I | 1 |
| Stehlich, G | 1 |
| van Parys, G | 1 |
| Evenepoel, C | 1 |
| van Damme, B | 1 |
| Desmet, VJ | 1 |
| Holub, PG | 1 |
| Hubbard, ER | 1 |
| Daniel, CR | 1 |
| Lawson, LA | 1 |
| Stepanova, ZhV | 1 |
| Smol'iakova, LL | 1 |
| Nilsen, A | 1 |
| Høvding, G | 1 |
| Hersle, K | 1 |
| Mobacken, H | 1 |
| Moberg, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Feedback Control of FSH Secretion in the Human Male[NCT00392457] | 175 participants (Anticipated) | Interventional | 1995-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
24 reviews available for ketoconazole and Nail Fungus
| Article | Year |
|---|---|
Pediatric Onychomycosis: The Emerging Role of Topical Therapy.
Topics: Administration, Topical; Adult; Age Factors; Antifungal Agents; Child; Ciclopirox; Family; Humans; I | 2017 |
The use of oral antifungal agents to treat onychomycosis.
Topics: Administration, Oral; Antifungal Agents; Drug Interactions; Fluconazole; Griseofulvin; Humans; Itrac | 2003 |
The systemic treatment of onychomycosis.
Topics: Antifungal Agents; Foot Dermatoses; Griseofulvin; Humans; Itraconazole; Ketoconazole; Naphthalenes; | 2004 |
Fungal nail infections.
Topics: Antifungal Agents; Fluconazole; Griseofulvin; Humans; Itraconazole; Ketoconazole; Naphthalenes; Onyc | 2005 |
Fungal toenail infections.
Topics: Antifungal Agents; Fluconazole; Griseofulvin; Humans; Itraconazole; Ketoconazole; Naphthalenes; Onyc | 2006 |
Onychomycosis.
Topics: Adolescent; Adult; Age Factors; Aged; Antifungal Agents; Arthrodermataceae; Child; Child, Preschool; | 1983 |
Ketoconazole.
Topics: Candidiasis; Candidiasis, Chronic Mucocutaneous; Candidiasis, Oral; Chemical Phenomena; Chemistry; C | 1984 |
The systemic treatment of onychomycosis.
Topics: Administration, Oral; Antifungal Agents; Fluconazole; Foot Dermatoses; Griseofulvin; Humans; Itracon | 1995 |
Oral therapeutic agents in fungal nail disease.
Topics: Administration, Oral; Allylamine; Antifungal Agents; Fluconazole; Griseofulvin; Humans; Itraconazole | 1994 |
Cost-effectiveness analysis for onychomycosis therapy in Canada from a government perspective.
Topics: Antifungal Agents; Canada; Cost-Benefit Analysis; Foot Dermatoses; Griseofulvin; Hand Dermatoses; Hu | 1994 |
A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. The Onychomycosis Study Group.
Topics: Antifungal Agents; Cost-Benefit Analysis; Decision Support Techniques; Foot Dermatoses; Griseofulvin | 1994 |
Onychomycosis. Agents of choice.
Topics: Administration, Cutaneous; Administration, Oral; Antifungal Agents; Candidiasis, Cutaneous; Fluconaz | 1993 |
New approaches to the treatment of onychomycosis.
Topics: Adult; Antifungal Agents; Humans; Itraconazole; Ketoconazole; Male; Naphthalenes; Onychomycosis; Ter | 1993 |
[Oral antifungal drugs].
Topics: Administration, Oral; Antifungal Agents; Dermatomycoses; Drug Administration Schedule; Humans; Itrac | 1995 |
Childhood white superficial onychomycosis caused by Trichophyton rubrum: report of seven cases and review of the literature.
Topics: Allylamine; Antifungal Agents; Child; Child, Preschool; Ciclopirox; Coloring Agents; Female; Foot De | 1997 |
Current trends in onychomycosis therapy: a literature review.
Topics: Antifungal Agents; Fluconazole; Humans; Itraconazole; Ketoconazole; Naphthalenes; Onychomycosis; Ter | 1997 |
Traditional approaches to treatment of onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Debridement; Foot Dermatoses; Griseofulvin; Humans; Keto | 1997 |
[Superficial mycoses in immunosuppressed patients].
Topics: Adult; Antifungal Agents; Candidiasis, Cutaneous; Candidiasis, Oral; Candidiasis, Vulvovaginal; Chil | 1995 |
Onychomycosis: pathogenesis, diagnosis, and management.
Topics: Adult; Antifungal Agents; Child; Diagnosis, Differential; Female; Fluconazole; Foot Dermatoses; Hand | 1998 |
An evaluation of intermittent therapies used to treat onychomycosis and other dermatomycoses with the oral antifungal agents.
Topics: Administration, Oral; Antifungal Agents; Clinical Trials as Topic; Dermatomycoses; Drug Administrati | 2000 |
A plea to bridge the gap between antifungals and the management of onychomycosis.
Topics: Antifungal Agents; Fluconazole; Humans; Itraconazole; Ketoconazole; Naphthalenes; Onychomycosis; Ter | 2001 |
Oral treatments for toenail onychomycosis: a systematic review.
Topics: Administration, Oral; Antifungal Agents; Dose-Response Relationship, Drug; Drug Administration Sched | 2002 |
Ketoconazole-induced fulminant hepatitis necessitating liver transplantation.
Topics: Candidiasis; Chemical and Drug Induced Liver Injury; Female; Humans; Ketoconazole; Liver Transplanta | 1991 |
Onychomycosis.
Topics: Arthrodermataceae; Candida; Diagnosis, Differential; Griseofulvin; Humans; Ketoconazole; Onychomycos | 1987 |
14 trials available for ketoconazole and Nail Fungus
| Article | Year |
|---|---|
Therapeutic efficacy of topical OLEOZON® in patients suffering from onychomycosis.
Topics: Administration, Topical; Adult; Aged; Antifungal Agents; Female; Humans; Ketoconazole; Male; Middle | 2011 |
Combination therapy of once-weekly fluconazole (100, 150, or 300 mg) with topical application of ketoconazole cream in the treatment of onychomycosis.
Topics: Administration, Oral; Administration, Topical; Adult; Aged; Aged, 80 and over; Antifungal Agents; Do | 2004 |
Combination of surgical avulsion and topical therapy for single nail onychomycosis: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Bandages; Child; Combined Modality Therapy; Drug Adminis | 2007 |
[Oral long-term treatment of onychomycoses with ketoconazole (author's transl)].
Topics: Administration, Oral; Adult; Aged; Antifungal Agents; Clinical Trials as Topic; Humans; Imidazoles; | 1980 |
Further experiences with ketoconazole in the treatment of onychomycosis.
Topics: Adolescent; Adult; Aged; Candida; Clinical Trials as Topic; Female; Humans; Imidazoles; Ketoconazole | 1981 |
A method for the determination of drug effectiveness in onychomycosis. Trials with ketoconazole and griseofulvin ultramicrosize.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Foot Dermatoses; Gri | 1983 |
Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study.
Topics: Adult; Aged; Alanine Transaminase; Antifungal Agents; Chemical and Drug Induced Liver Injury; Cohort | 1997 |
Skin and nail mycoses: treatment with ketoconazole, a new oral antimycotic agent.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Chemical Phenomena; Chemistry; Child; Child, Preschool; | 1979 |
Efficacy and safety of itraconazole in the long-term treatment of onychomycosis.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Arthrodermataceae; Dermatomycoses; Drug Administration S | 1992 |
Onychomycosis treated with itraconazole or griseofulvin alone with and without a topical antimycotic or keratolytic agent.
Topics: Administration, Topical; Adult; Antifungal Agents; Drug Therapy, Combination; Emollients; Female; Fo | 1991 |
Itraconazole in onychomycosis. Open and double-blind studies.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Child; Double-Blind Method; Female; Follow-Up Studies; H | 1990 |
Oral ketoconazole as an alternative to griseofulvin in recalcitrant dermatophyte infections and onychomycosis.
Topics: Administration, Oral; Adult; Child; Clinical Trials as Topic; Dermatomycoses; Double-Blind Method; G | 1985 |
[Experience with nizoral treatment of patients with rubromycosis].
Topics: Adolescent; Adult; Clinical Trials as Topic; Female; Hand Dermatoses; Humans; Ketoconazole; Male; Mi | 1988 |
[Ketoconazole in onychomycosis].
Topics: Adult; Clinical Trials as Topic; Female; Follow-Up Studies; Foot Dermatoses; Hand Dermatoses; Humans | 1985 |
53 other studies available for ketoconazole and Nail Fungus
| Article | Year |
|---|---|
Unusual dermatomycoses caused by Nannizzia nana: the geophilic origin of human infections.
Topics: Administration, Oral; Administration, Topical; Adult; Aged; Antifungal Agents; Arthrodermataceae; De | 2020 |
Cross-Linked Fluorescent Supramolecular Nanoparticles for Intradermal Controlled Release of Antifungal Drug-A Therapeutic Approach for Onychomycosis.
Topics: Animals; Antifungal Agents; Cross-Linking Reagents; Female; Fluorescent Dyes; Foot Dermatoses; Ketoc | 2018 |
Formulation evaluation of ketoconazole microemulsion-loaded hydrogel with nigella oil as a penetration enhancer.
Topics: Administration, Topical; Animals; Antifungal Agents; Aspergillus niger; Candida albicans; Delayed-Ac | 2019 |
Transungual delivery of ketoconazole using novel lacquer formulation.
Topics: Antifungal Agents; Chemistry, Pharmaceutical; Drug Delivery Systems; Humans; Ketoconazole; Lacquer; | 2013 |
Onychomycosis in diabetic patients in Fako Division of Cameroon: prevalence, causative agents, associated factors and antifungal sensitivity patterns.
Topics: Adult; Aged; Aged, 80 and over; Amphotericin B; Antifungal Agents; Cameroon; Cross-Sectional Studies | 2016 |
Cutaneous malasseziasis: four case reports of atypical dermatitis and onychomycosis caused by Malassezia.
Topics: Administration, Topical; Adult; Biopsy, Needle; Child, Preschool; Dermatomycoses; Female; Follow-Up | 2010 |
First description of onychomycosis caused by Chrysosporium keratinophilum in captive Bennett's wallabies (Macropus rufogriseus rufogriseus).
Topics: Animals; Antifungal Agents; Chrysosporium; Female; Foot Dermatoses; Ketoconazole; Macropodidae; Male | 2011 |
[Modern antimycotics. What the treating physician needs to know].
Topics: Antifungal Agents; Arthrodermataceae; Child; Dermatomycoses; Fluconazole; Griseofulvin; Humans; Itra | 2004 |
Influence of human nail etching for the assessment of topical onychomycosis therapies.
Topics: Administration, Topical; Antifungal Agents; Calorimetry, Differential Scanning; Chemistry, Pharmaceu | 2004 |
Characterization of hot-melt extruded drug delivery systems for onychomycosis.
Topics: Adhesiveness; Administration, Topical; Antifungal Agents; Area Under Curve; Calorimetry, Differentia | 2007 |
Identification and in vitro antifungal susceptibility testing of 200 clinical isolates of Candida spp. responsible for fingernail infections.
Topics: Antifungal Agents; Brazil; Candida; Candidiasis; Ciclopirox; Fluconazole; Hand Dermatoses; Humans; I | 2007 |
[Resistance to azolic compounds in clinical Trichophyton spp. strains].
Topics: Adult; Antifungal Agents; Cross Infection; Drug Resistance, Fungal; Drug Resistance, Multiple, Funga | 2007 |
[Ketoconazole and onychomycosis].
Topics: Adolescent; Adult; Aged; Arthrodermataceae; Candidiasis; Female; Foot Dermatoses; Hand Dermatoses; H | 1984 |
[Ketoconazole-induced hepatitis. Case report].
Topics: Alanine Transaminase; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Female; g | 1983 |
[Research in the treatment of fungal infections].
Topics: Antifungal Agents; Candidiasis, Vulvovaginal; Dermatomycoses; Female; Humans; Imidazoles; Ketoconazo | 1982 |
Ketoconazole in the treatment of fungal infection. Clinical and laboratory studies.
Topics: Adolescent; Adult; Antifungal Agents; Candidiasis; Candidiasis, Chronic Mucocutaneous; Dermatomycose | 1983 |
[Hepatitis during the administration of ketoconazole (Nizoral)].
Topics: Adult; Antifungal Agents; Chemical and Drug Induced Liver Injury; Dermatomycoses; Female; Humans; Im | 1983 |
[Toxic hepatitis caused by ketoconazole (Nizoral)].
Topics: Adult; Antifungal Agents; Chemical and Drug Induced Liver Injury; Female; Humans; Imidazoles; Ketoco | 1983 |
Double-blind evaluation of ketoconazole in patients with onychomycosis.
Topics: Antifungal Agents; Double-Blind Method; Female; Humans; Imidazoles; Ketoconazole; Male; Onychomycosi | 1983 |
Treatment of onychomycosis with ketoconazole and nonsurgical avulsion of the affected nail.
Topics: Adult; Antifungal Agents; Drug Therapy, Combination; Female; Humans; Imidazoles; Ketoconazole; Male; | 1983 |
[Ketoconazole--a change in antimycotic therapy?].
Topics: Aged; Antifungal Agents; Candidiasis, Cutaneous; Chemical and Drug Induced Liver Injury; Dermatomyco | 1983 |
[Preliminary experiences in the treatment of onychomycosis with ketoconazole].
Topics: Administration, Oral; Adult; Aged; Antifungal Agents; Candida; Humans; Imidazoles; Ketoconazole; Mid | 1983 |
Fatal hepatitis associated with ketoconazole therapy.
Topics: Aged; Chemical and Drug Induced Liver Injury; Female; Humans; Ketoconazole; Onychomycosis | 1984 |
Oral candidiasis and multiple myeloma. An unusual association.
Topics: Candidiasis, Oral; Female; Humans; Immunocompromised Host; Ketoconazole; Middle Aged; Multiple Myelo | 1994 |
[Oral treatment of onychomycosis of the toe nails; comparison of cost-effectiveness of griseofulvin, itraconazole, ketoconazole and terbinafine].
Topics: Administration, Oral; Antifungal Agents; Cost-Benefit Analysis; Drug Costs; Griseofulvin; Humans; It | 1994 |
Onychomycosis due to Pityrosporum.
Topics: Adult; Aged; Chloroform; Female; Hand Dermatoses; Humans; Ketoconazole; Malassezia; Male; Miconazole | 1993 |
[Liver damage during administration of itraconazole (Trisporal)].
Topics: Aged; Antifungal Agents; Aspergillosis, Allergic Bronchopulmonary; Chemical and Drug Induced Liver I | 1993 |
Therapeutic efficacy of terbinafine in the treatment of three children with tinea tonsurans.
Topics: Antifungal Agents; Child; Female; Griseofulvin; Hand Dermatoses; Humans; Ketoconazole; Microsporum; | 1996 |
Ketoconazole-induced hepatotoxicity.
Topics: Adult; Antifungal Agents; Chemical and Drug Induced Liver Injury; Cohort Studies; Female; Humans; Hy | 1997 |
A questionnaire study on the management of onychomycosis: a Canadian perspective.
Topics: Administration, Oral; Antifungal Agents; Canada; Dermatology; Female; Foot Dermatoses; Griseofulvin; | 1998 |
Aspergillus versicolor as cause of onychomycosis: report of 12 cases and susceptibility testing to antifungal drugs.
Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Aspergillus; Female; Foot Dermatoses; Humans; Itraco | 1998 |
[Acute hepatocytic necrosis during ketoconazole therapy for treatment of onychomycosis. National Foundation for Registry and Evaluation of Adverse Effects].
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Antifungal Agents; Chemical and Dr | 1998 |
The use of systemic antimycotics in dermatotherapy.
Topics: Administration, Cutaneous; Administration, Oral; Antifungal Agents; Cost-Benefit Analysis; Dermatomy | 2000 |
Posttreatment itraconazole levels in the nail. New implications for treatment in onychomycosis.
Topics: Antifungal Agents; Capsules; Chromatography, High Pressure Liquid; Drug Evaluation; Female; Fingers; | 1992 |
[New treatments of onychomycoses].
Topics: Administration, Topical; Antifungal Agents; Candidiasis; Ciclopirox; Fluconazole; Foot Dermatoses; H | 1992 |
Ketoconazole and hepatitis.
Topics: Chemical and Drug Induced Liver Injury; Female; Humans; Ketoconazole; Middle Aged; Onychomycosis | 1992 |
Itraconazole penetrates the nail via the nail matrix and the nail bed--an investigation in onychomycosis.
Topics: Adult; Aged; Female; Humans; Itraconazole; Ketoconazole; Male; Middle Aged; Nails; Onychomycosis | 1991 |
Treatment of onychomycosis with nail avulsion and topical ketoconazole.
Topics: Administration, Topical; Adolescent; Adult; Combined Modality Therapy; Female; Foot Dermatoses; Huma | 1991 |
Factors affecting plasma levels of ketoconazole during long-term treatment.
Topics: Adolescent; Adult; Dermatomycoses; Humans; Ketoconazole; Liver Function Tests; Long-Term Care; Middl | 1989 |
[A comprehensive assessment of the phagocytic activity of the blood neutrophils in patients with rubromycosis treated with griseofulvin and nizoral].
Topics: Biological Products; Blood Bactericidal Activity; Combined Modality Therapy; Foot Dermatoses; Griseo | 1989 |
[Experience in treating patients with rubrophytosis with nizoral].
Topics: Adolescent; Adult; Aged; Chronic Disease; Drug Evaluation; Female; Foot Dermatoses; Hand Dermatoses; | 1989 |
An evaluation of itraconazole in the management of onychomycosis.
Topics: Adult; Aged; Antifungal Agents; Drug Evaluation; Female; Foot Dermatoses; Hand Dermatoses; Humans; I | 1988 |
Effects of long-term ketoconazole therapy on serum lipid levels.
Topics: Adipose Tissue; Adult; Aged; Cholesterol; Female; Glucose Tolerance Test; Humans; Ketoconazole; Lipa | 1985 |
Onychomycosis.
Topics: Adult; Candida albicans; Candidiasis, Chronic Mucocutaneous; Foot Dermatoses; Glutaral; Griseofulvin | 1985 |
Current treatment of dermatophytoses.
Topics: Administration, Oral; Administration, Topical; Griseofulvin; Humans; Imidazoles; Ketoconazole; Onych | 1986 |
Consensus of the role and positioning of the imidazoles in the treatment of dermatophytosis.
Topics: Administration, Oral; Administration, Topical; Antifungal Agents; Griseofulvin; Humans; Imidazoles; | 1986 |
Lichenoid lesions of oral mucosa associated with ketoconazole.
Topics: Adult; Candidiasis, Oral; Female; Humans; Ketoconazole; Lichen Planus; Male; Middle Aged; Mouth Dise | 1986 |
Long term post-treatment follow-up of onychomycoses treated with ketoconazole.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Foot Dermatoses; Hand Dermato | 1986 |
Ketoconazole-induced hepatitis: a case with a definite cause-effect relationship.
Topics: Acute Disease; Biopsy, Needle; Chemical and Drug Induced Liver Injury; Female; Humans; Ketoconazole; | 1987 |
Ketoconazole in the treatment of onychomycosis.
Topics: Adult; Aged; Humans; Ketoconazole; Middle Aged; Onychomycosis | 1987 |
Tinea unguium.
Topics: Foot Dermatoses; Griseofulvin; Humans; Ketoconazole; Onychomycosis | 1987 |
Comparison of benefit against risk of ketoconazole therapy.
Topics: Adult; Aged; Candidiasis; Chemical and Drug Induced Liver Injury; Clinical Enzyme Tests; Dermatomyco | 1986 |
Long-term ketoconazole treatment of chronic acral dermatophyte infections.
Topics: Female; Griseofulvin; Hand Dermatoses; Humans; Ketoconazole; Male; Middle Aged; Onychomycosis; Recur | 1985 |